January 19, 2016 Synthetic Biologics Reports Positive Topline Data from Second Phase 2 Clinical Trial of SYN-010 in Patients with Irritable Bowel Syndrome with Constipation (IBS-C)
December 8, 2015 Synthetic Biologics' SYN-010 Lowered Breath Methane and Improved Stool Frequency in a Phase 2 Four Week Study in Patients with Irritable Bowel Syndrome with Constipation (IBS-C)
December 1, 2015 Synthetic Biologics Announces Positive Topline Results from First Phase 2a Clinical Trial of SYN-004, the Company's Candidate for the Prevention of C. difficile Infection
November 25, 2015 Synthetic Biologics Reports that Data from the Phase 2 Trimesta™ Clinical Trial for Relapsing-Remitting Multiple Sclerosis were Published by Lead Principal Investigator
November 24, 2015 Synthetic Biologics Announces Issuance of First Key U.S. Patent Directly Covering SYN-010, the Company's Novel Candidate for Irritable Bowel Syndrome with Constipation (IBS-C)
November 5, 2015 Synthetic Biologics Reports Third Quarter 2015 Financial Results and Operational Highlights
October 21, 2015 Grant Awarded to Synthetic Biologics' Academic Collaborator to Fund Further Evaluation of Monoclonal Antibody for the Prevention of Whooping Cough (Pertussis)
